Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Standard of Care Controlled, Parallel, Open-Label, Multicenter Pivotal Study to Evaluate the Efficacy and Safety of Avastin® in Combination With NaviFUS System Compared With Avastin® Alone for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NCT06496971 is registered in ClinicalTrials.gov with NaviFUS Corporation as lead sponsor.

NCT NCT06496971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06496971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Standard of Care Controlled, Parallel, Open-Label, Multicenter Pivotal Study to Evaluate the Efficacy and Safety of Avastin® in Combination With NaviFUS System Compared With Avastin® Alone for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
Lead sponsor
NaviFUS Corporation
Phase
Phase 3
Overall status
Recruiting
Start date
November 8, 2024
Completion date
March 31, 2027
Enrollment
32 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, brain tumor, recurrent, glioblastoma, glioblastoma multiforme, glioblastoma multiforme, adult, glioma, neoplasms, neoplasms, nerve tissue